{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:28:10Z","timestamp":1787923690456,"version":"build-2784847793"},"reference-count":163,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007048","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.msard.2026.107389","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:30:48Z","timestamp":1783726248000},"page":"107389","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Tailoring disease-modifying therapy approaches across multiple sclerosis sub-populations"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5053-8544","authenticated-orcid":false,"given":"Albert","family":"Aboseif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"Zeydan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabeela","family":"Nathoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhun H.","family":"Kantarci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilyana","family":"Amezcua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda","family":"Voskuhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riley","family":"Bove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le H.","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ontaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devon S.","family":"Conway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie M.","family":"Hersh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107389_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106579","article-title":"Navigating challenges and embracing opportunities toward achieving equitable multiple sclerosis care","volume":"101","author":"Aboseif","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2026.107389_bib0166","first-page":"13","article-title":"Evaluating heterogeneous treatment effects in pursuit of personalized multiple sclerosis care","volume":"24","author":"Aboseif","year":"2025","journal-title":"Pr. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.107389_bib0006","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ncl.2023.06.003","article-title":"Leveraging real-world evidence and observational studies in treating multiple sclerosis","volume":"42","author":"Aboseif","year":"2024","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.msard.2026.107389_bib0131","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ana.78086","article-title":"US Network of Pediatric MS Centers. Real-world effectiveness of switching to oral or infusion versus injectable disease-modifying therapy in pediatric Multiple sclerosis","volume":"99","author":"Abrams","year":"2026","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2026.107389_bib0077","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1097\/AOG.0000000000006078","article-title":"Anticipatory counseling regarding ovarian-factor fertility decline","volume":"146","year":"2025","journal-title":"Obs. Gynecol."},{"issue":"4","key":"10.1016\/j.msard.2026.107389_bib0098","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213967","article-title":"Effectiveness of disease-modifying therapies in patients with late-onset relapsing-remitting multiple sclerosis","volume":"105","author":"Al-Araji","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107389_bib0122","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pediatrneurol.2018.03.007","article-title":"Safety and efficacy of delayed-release dimethyl fumarate in pediatric patients with relapsing multiple sclerosis (FOCUS)","volume":"83","author":"Alroughani","year":"2018","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.msard.2026.107389_bib0123","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.606418","article-title":"Delayed-release dimethyl fumarate safety and efficacy in pediatric patients with relapsing-remitting multiple sclerosis","volume":"11","author":"Alroughani","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107389_bib0115","article-title":"Preliminary baseline characteristics and early follow-up in the COAST Study: anti-CD20 to ozanimod sequencing trial","author":"Alvarez","year":"2026","journal-title":"ACTRIMS Forum"},{"issue":"11-12","key":"10.1016\/j.msard.2026.107389_bib0011","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1177\/13524585241286988","article-title":"The current state of diversity, equity, and inclusion in multiple sclerosis research, clinical trials, and workforce","volume":"30","author":"Amezcua","year":"2024","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107389_bib0024","first-page":"3651","article-title":"One-year analysis of efficacy and safety data from black\/African American and Hispanic\/Latino people with relapsing multiple sclerosis receiving ocrelizumab treatment in the CHIMES trial (PL5. 005)","volume":"102","author":"Amezcua","year":"2024"},{"issue":"1","key":"10.1016\/j.msard.2026.107389_bib0002","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2217\/nmt-2021-0058","article-title":"Updates and advances in multiple sclerosis neurotherapeutics","volume":"13","author":"Amin","year":"2023","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.msard.2026.107389_bib0151","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103214","article-title":"Experiences of sexual and gender minority people living with multiple sclerosis in Northern California: an exploratory study","volume":"55","author":"Anderson","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2026.107389_bib0029","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000959","article-title":"Clinical and radiologic disease activity in pregnancy and postpartum in MS","volume":"8","author":"Anderson","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.msard.2026.107389_bib0119","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1136\/jnnp-2019-322138","article-title":"Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study","volume":"91","author":"Arnold","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2026.107389_bib0041","unstructured":"Aubagio (teriflunomide) [package insert]. Food and Drug Administration. Updated June 24, 2024. Accessed October 27, 2025."},{"issue":"12","key":"10.1016\/j.msard.2026.107389_bib0162","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1177\/13524585251383330","article-title":"A multicenter cohort of transgender and gender diverse people with multiple sclerosis","volume":"31","author":"Balshi","year":"2025","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107389_bib0128","series-title":"Presented at: 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)","article-title":"Efficacy and safety of ocrelizumab compared with fingolimod in paediatric relapsing-remitting MS: results of the Phase III OPERETTA 2 study","author":"Banwell","year":"2025"},{"issue":"3","key":"10.1016\/j.msard.2026.107389_bib0117","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1001\/jamaneurol.2023.5566","article-title":"Highly effective therapies as first-line treatment for pediatric-onset multiple sclerosis","volume":"81","author":"Benallegue","year":"2024","journal-title":"Jama Neurol."},{"issue":"11","key":"10.1016\/j.msard.2026.107389_bib0081","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1177\/1352458519865118","article-title":"Effect of assisted reproductive technology on multiple sclerosis relapses: case series and meta-analysis","volume":"26","author":"Bove","year":"2020","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2026.107389_bib0027","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ncl.2023.07.004","article-title":"Women's health and pregnancy in Multiple sclerosis","volume":"42","author":"Bove","year":"2024","journal-title":"Neurol. Clin."},{"issue":"1","key":"10.1016\/j.msard.2026.107389_bib0165","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12916-019-1345-2","article-title":"Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial data","volume":"17","author":"Bovis","year":"2019","journal-title":"BMC. Med."},{"issue":"8","key":"10.1016\/j.msard.2026.107389_bib0126","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jamaneurol.2022.1735","article-title":"Reinterpreting clinical trials in children with multiple sclerosis using a Bayesian approach","volume":"79","author":"Bovis","year":"2022","journal-title":"Jama Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107389_bib0033","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/cpt.2602","article-title":"Science-based approach to harmonize contraception recommendations in clinical trials and pharmaceutical labels","volume":"113","author":"Bowman","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.msard.2026.107389_bib0135","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16228","article-title":"Rituximab treatment in pediatric-onset multiple sclerosis","volume":"31","author":"Breu","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2026.107389_bib0074","unstructured":"Briumvi (Ublituximab) [package insert]. Food and Drug Administration. Updated 2025. Accessed October 30, 2025."},{"key":"10.1016\/j.msard.2026.107389_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104066","article-title":"Disease reactivation after fingolimod cessation in Multiple Sclerosis patients with pregnancy desire: A retrospective study","volume":"66","author":"Callens","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107389_bib0018","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.msard.2018.07.014","article-title":"Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study","volume":"25","author":"Cascione","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"Suppl 2","key":"10.1016\/j.msard.2026.107389_bib0145","first-page":"1454","article-title":"Discrimination in the United States: experiences of lesbian, gay, bisexual, transgender, and queer Americans","volume":"54","author":"Casey","year":"2019","journal-title":"Heal. V Res."},{"issue":"11","key":"10.1016\/j.msard.2026.107389_bib0118","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1056\/NEJMoa1800149","article-title":"Trial of Fingolimod versus interferon beta-1a in pediatric multiple sclerosis","volume":"379","author":"Chitnis","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.msard.2026.107389_bib0124","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S1474-4422(21)00364-1","article-title":"Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial","volume":"20","author":"Chitnis","year":"2021","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107389_bib0107","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jamaneurol.2024.4164","article-title":"Discontinuation of first-line disease-modifying therapy in patients with stable multiple sclerosis: the DOT-MS randomized clinical trial","volume":"82","author":"Coerver","year":"2025","journal-title":"Jama Neurol."},{"issue":"9856","key":"10.1016\/j.msard.2026.107389_bib0062","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.msard.2026.107389_bib0028","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJM199807303390501","article-title":"Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple sclerosis group","volume":"339","author":"Confavreux","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.msard.2026.107389_bib0106","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","article-title":"Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial","volume":"22","author":"Corboy","year":"2023","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2026.107389_bib0078","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/ana.23745","article-title":"Increase in multiple sclerosis activity after assisted reproduction technology","volume":"72","author":"Correale","year":"2012","journal-title":"Ann. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2026.107389_bib0013","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/archneur.62.11.1681","article-title":"Response to interferon beta-1a treatment in African American multiple sclerosis patients","volume":"62","author":"Cree","year":"2005","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107389_bib0019","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/archneurol.2011.45","article-title":"Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data","volume":"68","author":"Cree","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2026.107389_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103010","article-title":"OPERA I and OPERA II clinical investigators. Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies","volume":"52","author":"Cree","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2026.107389_bib0063","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/jc.2013-2201","article-title":"Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis","volume":"99","author":"Daniels","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.msard.2026.107389_bib0142","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000724","article-title":"Single-cycle rituximab-induced immunologic changes in children: enhanced in neuroimmunologic disease?","volume":"7","author":"Dey\u00e0-Mart\u00ednez","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"7","key":"10.1016\/j.msard.2026.107389_bib0104","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1007\/s00415-024-12384-3","article-title":"Management of multiple sclerosis in older adults: review of current evidence and future perspectives","volume":"271","author":"DiMauro","year":"2024","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.107389_bib0057","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/13524585221131486","article-title":"Cladribine and pregnancy in women with multiple sclerosis: the first cohort study","volume":"29","author":"Dost-Kovalsky","year":"2023","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2026.107389_bib0100","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/jnnp-2025-336513","article-title":"Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis","volume":"97","author":"Foong","year":"2026","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"8","key":"10.1016\/j.msard.2026.107389_bib0101","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/jnnp-2023-332883","article-title":"Comparing ocrelizumab to interferon\/glatiramer acetate in people with multiple sclerosis over age 60","volume":"95","author":"Foong","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.msard.2026.107389_bib0049","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/ene.13694","article-title":"Cocco E; i-MuST study group. Clinical activity after fingolimod cessation: disease reactivation or rebound?","volume":"25","author":"Frau","year":"2018","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.107389_bib0044","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/toxsci\/kfv321","article-title":"Elevated nuclear and cytoplasmic FTY720-phosphate in mouse embryonic fibroblasts suggests the potential for multiple mechanisms in FTY720-induced neural tube defects","volume":"150","author":"Gardner","year":"2016","journal-title":"Toxicol. Sci."},{"issue":"10","key":"10.1016\/j.msard.2026.107389_bib0048","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/jamaneurol.2025.2550","article-title":"Therapeutic management during pregnancy and relapse risk in women with multiple sclerosis","volume":"82","author":"Gavoille","year":"2025","journal-title":"Jama Neurol."},{"key":"10.1016\/j.msard.2026.107389_bib0092","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2024.578368","article-title":"As time goes by: treatment challenges in elderly people with multiple sclerosis","volume":"391","author":"Gelibter","year":"2024","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2026.107389_bib0132","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12883-015-0433-y","article-title":"Natalizumab in the pediatric MS population: results of the Italian registry","volume":"15","author":"Ghezzi","year":"2015","journal-title":"BMC. Neurol."},{"key":"10.1016\/j.msard.2026.107389_bib0045","unstructured":"Gilenya (fingolimod) [package insert]. Food and Drug Administration. Updated 2025. Accessed October 27, 2025."},{"key":"10.1016\/j.msard.2026.107389_bib0111","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106552","article-title":"De-escalation of disease modifying therapies: A retrospective, observational single center study","volume":"100","author":"Goldschmidt","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2026.107389_bib0076","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200106","article-title":"Inflammatory activity after diverse fertility treatments: A multicenter analysis in the modern multiple sclerosis treatment era","volume":"10","author":"Graham","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.msard.2026.107389_bib0040","article-title":"Practical considerations for managing pregnancy in patients with multiple sclerosis: dispelling the myths","volume":"14","author":"Graham","year":"2024","journal-title":"Neurol. Clin. Pr."},{"issue":"1","key":"10.1016\/j.msard.2026.107389_bib0095","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(22)00184-3","article-title":"Ageing and multiple sclerosis","volume":"22","author":"Graves","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107389_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103347","article-title":"Teriflunomide levels in women whose male sexual partner is on teriflunomide for relapsing multiple sclerosis","volume":"57","author":"Guarnaccia","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2026.107389_bib0086","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1007\/s00415-023-12047-9","article-title":"Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study","volume":"271","author":"Habbestad","year":"2024","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107389_bib0032","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/jnnp-2023-331525","article-title":"Early postpartum treatment strategies and early postpartum relapses in women with active multiple sclerosis","volume":"95","author":"Haben","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2026.107389_bib0035","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420951072","article-title":"Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and Sweden","volume":"13","author":"Hakkarainen","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"7","key":"10.1016\/j.msard.2026.107389_bib0046","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","article-title":"Rebound syndrome in patients with multiple sclerosis after cessation of Fingolimod treatment","volume":"73","author":"Hatcher","year":"2016","journal-title":"Jama Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.107389_bib0025","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"OPERA I and OPERA II clinical investigators. Ocrelizumab versus Interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2026.107389_bib0038","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/13524585231220232","article-title":"Final analysis of 379 pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registry","volume":"30","author":"Hellwig","year":"2024","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2026.107389_bib0037","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001114","article-title":"Interim analysis of pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registry","volume":"9","author":"Hellwig","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.msard.2026.107389_bib0056","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200438","article-title":"Pregnancy and infant outcomes in Multiple sclerosis: findings from the Global MAPLE-MS Pharmacovigilance Program","volume":"12","author":"Hellwig","year":"2025","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"15_supplement","key":"10.1016\/j.msard.2026.107389_bib0051","doi-asserted-by":"crossref","first-page":"P5","DOI":"10.1212\/WNL.90.15_supplement.P5.032","article-title":"Disease activity during pregnancy after Fingolimod withdrawal due to planning a pregnancy in women with multiple sclerosis (P5. 032)","volume":"90","author":"Hemat","year":"2018","journal-title":"Neurology."},{"issue":"8","key":"10.1016\/j.msard.2026.107389_bib0144","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1001\/jamaneurol.2023.2125","article-title":"Initiation patterns of disease-modifying therapies for multiple sclerosis among US adults and children, 2001 through 2020","volume":"80","author":"Henderson","year":"2023","journal-title":"Jama Neurol."},{"issue":"6","key":"10.1016\/j.msard.2026.107389_bib0112","first-page":"e53","article-title":"Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practice","volume":"10","author":"Hersh","year":"2020","journal-title":"Neurol. Clin. Pr."},{"key":"10.1016\/j.msard.2026.107389_bib0164","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105847","article-title":"A 2-stage model of heterogenous treatment effects for brain atrophy in multiple sclerosis utilizing the MS PATHS research network","volume":"91","author":"Hersh","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2026.107389_bib0069","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2026.107389_bib0109","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1177\/1352458518765656","article-title":"Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60","volume":"25","author":"Hua","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107389_bib0084","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1001\/jamaneurol.2024.3062","article-title":"Differential diagnosis of suspected multiple sclerosis in pediatric and late-onset populations: A review","volume":"81","author":"Hua","year":"2024","journal-title":"Jama Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.107389_bib0021","first-page":"87","article-title":"B-cell-targeted therapies for black vs white Americans with relapsing multiple sclerosis","volume":"35","author":"Hylton-Gordon","year":"2025","journal-title":"Ethn. Dis."},{"issue":"5","key":"10.1016\/j.msard.2026.107389_bib0082","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.rbmo.2020.01.013","article-title":"Live birth in women with multiple sclerosis receiving assisted reproduction","volume":"40","author":"J\u00f8lving","year":"2020","journal-title":"Reprod. Biomed. Online"},{"issue":"5","key":"10.1016\/j.msard.2026.107389_bib0108","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamaneurol.2024.0395","article-title":"High-efficacy therapy discontinuation vs continuation in patients 50 years and older with nonactive MS","volume":"81","author":"Jouvenot","year":"2024","journal-title":"Jama Neurol."},{"key":"10.1016\/j.msard.2026.107389_bib0152","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101440","article-title":"Gender identity and sexual orientation affect health care satisfaction, but not utilization, in persons with Multiple Sclerosis","volume":"37","author":"Khayambashi","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107389_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocn.2026.111977","article-title":"Maternal and neonatal outcomes following natalizumab use during pregnancy in women with multiple sclerosis: A multicenter observational study","volume":"148","author":"Kitsos","year":"2026","journal-title":"J. Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.msard.2026.107389_bib0014","first-page":"221","article-title":"Response to disease modifying therapies in African Americans with multiple sclerosis","volume":"22","author":"Klineova","year":"2012","journal-title":"Ethn. Dis."},{"issue":"1","key":"10.1016\/j.msard.2026.107389_bib0072","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000913","article-title":"Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: A cohort study from Germany","volume":"8","author":"K\u00fcmpfel","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"22","key":"10.1016\/j.msard.2026.107389_bib0087","doi-asserted-by":"crossref","first-page":"e1954","DOI":"10.1212\/WNL.0000000000005612","article-title":"Incidence of MS has increased markedly over six decades in Denmark particularly with late onset and in women","volume":"90","author":"Koch-Henriksen","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2026.107389_bib0120","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2021-000215","article-title":"Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIGMS Study","volume":"4","author":"Krupp","year":"2022","journal-title":"BMJ Neurol. Open."},{"issue":"4","key":"10.1016\/j.msard.2026.107389_bib0034","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1474-4422(22)00426-4","article-title":"Family planning considerations in people with multiple sclerosis","volume":"22","author":"Krysko","year":"2023","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.107389_bib0130","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25737","article-title":"Real-world effectiveness of initial disease-modifying therapies in pediatric multiple sclerosis","volume":"88","author":"Krysko","year":"2020","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107389_bib0138","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210213","article-title":"Study of the Association between Menarche and Disease Course in Pediatric Multiple sclerosis","volume":"104","author":"Krysko","year":"2025","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2026.107389_bib0141","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jaci.2021.03.041","article-title":"Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients","volume":"148","author":"Labrosse","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"issue":"8028","key":"10.1016\/j.msard.2026.107389_bib0157","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41586-024-07789-z","article-title":"Immune system adaptation during gender-affirming testosterone treatment","volume":"633","author":"Lakshmikanth","year":"2024","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.msard.2026.107389_bib0146","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2105\/AJPH.2023.307333","article-title":"Self-reported barriers to care among sexual and gender minority people with disabilities: findings from the PRIDE study, 2019-2020","volume":"113","author":"Lamba","year":"2023","journal-title":"Am. J. Public Health"},{"issue":"11-12","key":"10.1016\/j.msard.2026.107389_bib0039","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1177\/13524585241274600","article-title":"Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy","volume":"30","author":"Landi","year":"2024","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107389_bib0067","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2022-329657","article-title":"Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis","author":"Landi","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.msard.2026.107389_bib0050","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s00415-021-10658-8","article-title":"What happens after fingolimod discontinuation? A multicentre real-life experience","volume":"269","author":"Landi","year":"2022","journal-title":"J. Neurol."},{"issue":"18","key":"10.1016\/j.msard.2026.107389_bib0007","doi-asserted-by":"crossref","first-page":"e1818","DOI":"10.1212\/WNL.0000000000200151","article-title":"Racial and ethnic disparities in multiple sclerosis prevalence","volume":"98","author":"Langer-Gould","year":"2022","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2026.107389_bib0153","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.msard.2017.02.001","article-title":"Health-care disparities stemming from sexual orientation of Italian patients with Multiple Sclerosis: A cross-sectional web-based study","volume":"13","author":"Lavorgna","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107389_bib0061","unstructured":"Lemtrada (Alemtuzumab) [package insert]. Food and Drug Administration. Updated 2025. Accessed October 30, 2025."},{"issue":"9","key":"10.1016\/j.msard.2026.107389_bib0026","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40263-025-01205-4","article-title":"Multiple sclerosis in people of diverse racial and ethnic backgrounds: presentation, disease course, and interactions with disease-modifying therapy","volume":"39","author":"Li","year":"2025","journal-title":"CNS. Drugs"},{"key":"10.1016\/j.msard.2026.107389_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102157","article-title":"Exposure to medication for neurological disease in pregnancy - time to consider the long-term implications?","volume":"63","author":"Liu","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"8","key":"10.1016\/j.msard.2026.107389_bib0139","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31779","article-title":"Hypogammaglobulinemia in children receiving targeted immunotherapies for B lineage malignancies: practical guidance for assessment and management","volume":"72","author":"Long","year":"2025","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.msard.2026.107389_bib0093","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1197212","article-title":"Impact of aging on treatment considerations for multiple sclerosis patients","volume":"14","author":"Macaron","year":"2023","journal-title":"Front. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2026.107389_bib0055","doi-asserted-by":"crossref","first-page":"jjaf129","DOI":"10.1093\/ecco-jcc\/jjaf129","article-title":"Global Consensus Group for pregnancy and IBD. Global Consensus Statement on the management of pregnancy in inflammatory bowel disease","volume":"19","author":"Mahadevan","year":"2025","journal-title":"J. Crohns. Colitis."},{"issue":"2","key":"10.1016\/j.msard.2026.107389_bib0080","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200371","article-title":"Assessing the risk of relapse after In vitro fertilization in women with multiple sclerosis","volume":"12","author":"Mainguy","year":"2025","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"9","key":"10.1016\/j.msard.2026.107389_bib0008","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1177\/13524585231189677","article-title":"Enhancing diversity of clinical trial populations in multiple sclerosis","volume":"29","author":"Marrie","year":"2023","journal-title":"Mult. Scler."},{"issue":"13","key":"10.1016\/j.msard.2026.107389_bib0094","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1212\/WNL.0b013e3181d6b125","article-title":"Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis","volume":"74","author":"Marrie","year":"2010","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.msard.2026.107389_bib0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.45619","article-title":"Socioeconomic and regional disparities in industry-sponsored clinical trials in Multiple sclerosis","volume":"6","author":"Marti","year":"2023","journal-title":"JAMa Netw. Open."},{"key":"10.1016\/j.msard.2026.107389_bib0058","unstructured":"Mavenclad (Cladribine) [package insert]. Food and Drug Administration. Updated 2025. Accessed October 30, 2025."},{"issue":"2","key":"10.1016\/j.msard.2026.107389_bib0143","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.36321","article-title":"Association of Rituximab use with adverse events in children, adolescents, and young adults","volume":"4","author":"McAtee","year":"2021","journal-title":"Jama Netw. Open."},{"issue":"8","key":"10.1016\/j.msard.2026.107389_bib0001","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"Jama, J. Am. Med. Assoc."},{"issue":"8","key":"10.1016\/j.msard.2026.107389_bib0079","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/jnnp-2012-302235","article-title":"Increased risk of multiple sclerosis relapse after in vitro fertilisation","volume":"83","author":"Michel","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.msard.2026.107389_bib0090","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208051","article-title":"Clinical characteristics and long-term outcomes of late-onset multiple sclerosis: A Swedish nationwide study","volume":"102","author":"Mouresan","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107389_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1215774","article-title":"Do magnetic resonance imaging features differ between persons with multiple sclerosis of various races and ethnicities?","volume":"14","author":"Nathoo","year":"2023","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.107389_bib0154","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41582-024-01042-x","article-title":"Exploring the role of sex hormones and gender diversity in multiple sclerosis","volume":"21","author":"Nesbitt","year":"2025","journal-title":"Nat. Rev. Neurol."},{"issue":"14","key":"10.1016\/j.msard.2026.107389_bib0163","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1177\/13524585251341174","article-title":"Gender-affirming interventions and prognosis in multiple sclerosis","volume":"31","author":"Neyal","year":"2025","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107389_bib0096","doi-asserted-by":"crossref","unstructured":"H.S Ng, J. Graf, F. Zhu, E. Kingwell, O. Aktas, P. Albrecht, H.P Hartung, S.G Meuth, C. Evans, J.D Fisk, R.A Marrie, Y. Zhao, H. Tremlett Disease-modifying drug uptake and health service use in the ageing MS population. Front immunol. 2022 Jan 13;12:794075. doi: 10.3389\/fimmu.2021.794075. PMID: 35095869; PMCID: PMC8792855.","DOI":"10.3389\/fimmu.2021.794075"},{"issue":"9","key":"10.1016\/j.msard.2026.107389_bib0155","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1111\/imj.16413","article-title":"Gender-affirming hormone therapy for transgender and gender-diverse adults in Australia","volume":"54","author":"Nolan","year":"2024","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.msard.2026.107389_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102146","article-title":"CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators. Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years","volume":"43","author":"Oh","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"24","key":"10.1016\/j.msard.2026.107389_bib0015","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1212\/WNL.0000000000200791","article-title":"Advancing care and outcomes for African American patients with multiple sclerosis","volume":"98","author":"Okai","year":"2022","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2026.107389_bib0004","doi-asserted-by":"crossref","first-page":"e880","DOI":"10.1212\/WNL.0000000000013230","article-title":"Enrollment of Non-White participants and reporting of race and ethnicity in phase III trials of Multiple sclerosis DMTs: a systematic review","volume":"98","author":"Onuorah","year":"2022","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2026.107389_bib0140","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees","volume":"149","author":"Otani","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"issue":"13","key":"10.1016\/j.msard.2026.107389_bib0161","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1177\/1352458515627205","article-title":"Gender identity disorders and multiple sclerosis risk: A national record-linkage study","volume":"22","author":"Pakpoor","year":"2016","journal-title":"Mult. Scler."},{"issue":"4-5","key":"10.1016\/j.msard.2026.107389_bib0148","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1177\/10497323241309583","article-title":"It's like a double whammy!\": A photo-phenomenological analysis of the experiences of Lesbian, Gay, Bisexual, and queer people living with multiple sclerosis","volume":"35","author":"Papaloukas","year":"2025","journal-title":"Qual. Heal. Res."},{"issue":"1","key":"10.1016\/j.msard.2026.107389_bib0099","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1212\/WNL.0000000000001094","article-title":"Relapses and disability accumulation in progressive multiple sclerosis","volume":"84","author":"Paz Sold\u00e1n","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107389_bib0102","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2024.123052","article-title":"Selection of disease modifying therapies in multiple sclerosis based on patient's age and disease activity: data from a nationwide registry","volume":"461","author":"Piedrabuena","year":"2024","journal-title":"J. Neurol. Sci."},{"issue":"8","key":"10.1016\/j.msard.2026.107389_bib0003","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1177\/13524585241254283","article-title":"Race and ethnicity in multiple sclerosis phase 3 clinical trials: a systematic review","volume":"30","author":"Ponzano","year":"2024","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107389_bib0068","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.715195","article-title":"Drug and neurofilament levels in serum and breastmilk of women with multiple sclerosis exposed to Natalizumab during pregnancy and lactation","volume":"12","author":"Proschmann","year":"2021","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.msard.2026.107389_bib0110","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40263-023-01038-z","article-title":"Stopping disease-modifying treatments in Multiple sclerosis: A systematic review and meta-analysis of real-world studies","volume":"37","author":"Prosperini","year":"2023","journal-title":"CNS. Drugs"},{"key":"10.1016\/j.msard.2026.107389_bib0085","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/jnnp-2022-329049","article-title":"Shift of multiple sclerosis onset towards older age","volume":"93","author":"Prosperini","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.msard.2026.107389_bib0097","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213744","article-title":"Use of disease-modifying therapies in patients with late-onset multiple sclerosis","volume":"105","author":"Robin","year":"2025","journal-title":"Neurology"},{"issue":"17","key":"10.1016\/j.msard.2026.107389_bib0066","doi-asserted-by":"crossref","first-page":"e1926","DOI":"10.1212\/WNL.0000000000201029","article-title":"Disease reactivation after cessation of Disease-modifying therapy in patients with relapsing-remitting multiple sclerosis","volume":"99","author":"Roos","year":"2022","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2026.107389_bib0150","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210119","article-title":"Advancing LGBTQI+ Equity in neurology: an AAN position statement","volume":"104","author":"Rosendale","year":"2025","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2026.107389_bib0149","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1212\/WNL.0000000000007829","article-title":"American Academy of Neurology members' preparedness to treat sexual and gender minorities","volume":"93","author":"Rosendale","year":"2019","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2026.107389_bib0147","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamaneurol.2020.5536","article-title":"Sexual and Gender minority health in Neurology: A scoping review","volume":"78","author":"Rosendale","year":"2021","journal-title":"Jama Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107389_bib0054","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001183","article-title":"Transitioning from S1P receptor modulators to B cell-depleting therapies in multiple sclerosis: clinical, radiographic, and laboratory data","volume":"9","author":"Rowles","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.msard.2026.107389_bib0052","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40263-021-00798-w","article-title":"Sphingosine 1-phosphate receptor modulators for multiple sclerosis","volume":"35","author":"Roy","year":"2021","journal-title":"CNS. Drugs"},{"issue":"6","key":"10.1016\/j.msard.2026.107389_bib0016","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1177\/1756285616661929","article-title":"Efficacy and tolerability of dimethyl fumarate in White-, African-and Hispanic-Americans with multiple sclerosis","volume":"9","author":"Ryerson","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2026.107389_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103830","article-title":"Faster B-cell repletion after anti-CD20 infusion in black patients compared to white patients with neurologic diseases","volume":"63","author":"Saidenberg","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2026.107389_bib0036","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7224\/1537-2073.2016-079","article-title":"Pregnancy outcomes from the branded glatiramer acetate Pregnancy database","volume":"20","author":"Sandberg-Wollheim","year":"2018","journal-title":"Int. J. MS. Care"},{"key":"10.1016\/j.msard.2026.107389_bib0133","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejpn.2023.05.001","article-title":"KidBiosep cohort study. Treatments of paediatric multiple sclerosis: efficacy and tolerance in a longitudinal follow-up study","volume":"45","author":"Saponaro","year":"2023","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2026.107389_bib0031","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/jnnp-2022-330533","article-title":"Postpartum relapse risk in multiple sclerosis: a systematic review and meta-analysis","volume":"94","author":"Schubert","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.msard.2026.107389_bib0156","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261312","article-title":"The effect of transdermal gender-affirming hormone therapy on markers of inflammation and hemostasis","volume":"17","author":"Schutte","year":"2022","journal-title":"PLoS. One"},{"issue":"4","key":"10.1016\/j.msard.2026.107389_bib0070","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200264","article-title":"Neonatal B-cell levels and infant health in newborns potentially exposed to anti-CD20 monoclonal antibodies during pregnancy or lactation","volume":"11","author":"Schwake","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"8","key":"10.1016\/j.msard.2026.107389_bib0105","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40263-021-00810-3","article-title":"Predicting infection risk in multiple sclerosis patients treated with Ocrelizumab: A retrospective cohort study","volume":"35","author":"Seery","year":"2021","journal-title":"CNS. Drugs"},{"key":"10.1016\/j.msard.2026.107389_bib0159","first-page":"dgag141","article-title":"Cytokine dynamics following initiation of gender-affirming hormone therapy in transgender subjects","author":"Sertons","year":"2026","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.msard.2026.107389_bib0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.31581","article-title":"Pregnancy-related disease outcomes in women with moderate to severe multiple sclerosis disability","volume":"8","author":"Shipley","year":"2025","journal-title":"Jama Netw. Open."},{"issue":"6","key":"10.1016\/j.msard.2026.107389_bib0114","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/ene.12690","article-title":"Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials","volume":"22","author":"Signori","year":"2015","journal-title":"Eur. J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107389_bib0073","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000734","article-title":"Rituximab, MS, and pregnancy","volume":"7","author":"Smith","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"9","key":"10.1016\/j.msard.2026.107389_bib0005","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1177\/13524585231189673","article-title":"Assessing heterogeneity of treatment effect in multiple sclerosis trials","volume":"29","author":"Sormani","year":"2023","journal-title":"Mult. Scler."},{"issue":"10","key":"10.1016\/j.msard.2026.107389_bib0083","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40263-023-01036-1","article-title":"Assisted reproductive technology and disease management in infertile women with multiple sclerosis","volume":"37","author":"Sparaco","year":"2023","journal-title":"CNS. Drugs"},{"issue":"7","key":"10.1016\/j.msard.2026.107389_bib0134","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208114","article-title":"Comparative effectiveness of Natalizumab, Fingolimod, and injectable therapies in pediatric-onset multiple sclerosis: A registry-based study","volume":"102","author":"Spelman","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107389_bib0136","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pediatrneurol.2024.12.015","article-title":"Safety and efficacy of Fingolimod and Ocrelizumab in pediatric patients with multiple sclerosis","volume":"164","author":"Spirek","year":"2025","journal-title":"Pediatr. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2026.107389_bib0065","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/jnnp-2023-332804","article-title":"Disease activity and neonatal outcomes after exposure to natalizumab throughout pregnancy","volume":"95","author":"Thiel","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.msard.2026.107389_bib0075","article-title":"Fertility treatments in patients with medical conditions","volume":"25","author":"Uppal","year":"2025","journal-title":"Clin. Med. L"},{"issue":"8","key":"10.1016\/j.msard.2026.107389_bib0060","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1007\/s10072-020-04975-5","article-title":"Pregnancy outcomes in alemtuzumab treated women with multiple sclerosis: a case series","volume":"42","author":"Valeria","year":"2021","journal-title":"Neurol. Sci."},{"issue":"2","key":"10.1016\/j.msard.2026.107389_bib0160","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1093\/ejendo\/lvad170","article-title":"Cardiovascular disease in transgender people: a systematic review and meta-analysis","volume":"190","author":"van Zijverden","year":"2024","journal-title":"Eur. J. Endocrinol."},{"issue":"6","key":"10.1016\/j.msard.2026.107389_bib0088","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41582-019-0183-3","article-title":"Epidemiology and treatment of multiple sclerosis in elderly populations","volume":"15","author":"Vaughn","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"9","key":"10.1016\/j.msard.2026.107389_bib0121","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.30439","article-title":"Effect of Dimethyl Fumarate vs interferon \u03b2-1a in patients with pediatric-onset multiple sclerosis: the CONNECT randomized clinical trial","volume":"5","author":"Vermersch","year":"2022","journal-title":"Jama Netw. Open."},{"key":"10.1016\/j.msard.2026.107389_bib0113","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.799138","article-title":"Evolution of disease modifying therapy benefits and risks: an argument for de-escalation as a treatment paradigm for patients with multiple sclerosis","volume":"12","author":"Vollmer","year":"2022","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.107389_bib0071","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200349","article-title":"Pregnancy and infant outcomes in women with multiple sclerosis treated with Ocrelizumab","volume":"12","author":"Vukusic","year":"2025","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"7","key":"10.1016\/j.msard.2026.107389_bib0043","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1177\/1352458519843055","article-title":"Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: clinical study data and 5 years of post-marketing experience","volume":"26","author":"Vukusic","year":"2020","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.msard.2026.107389_bib0116","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1474-4422(14)70093-6","article-title":"Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research","volume":"13","author":"Waldman","year":"2014","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.msard.2026.107389_bib0089","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","article-title":"US Multiple Sclerosis Prevalence Workgroup. The prevalence of MS in the United States: A population-based estimate using health claims data","volume":"92","author":"Wallin","year":"2019","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/j.msard.2026.107389_bib0127","doi-asserted-by":"crossref","first-page":"e2538","DOI":"10.1212\/WNL.0000000000007572","article-title":"Clinical trials of disease-modifying agents in pediatric MS: opportunities, challenges, and recommendations from the IPMSSG","volume":"92","author":"Waubant","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107389_bib0091","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3389\/fneur.2017.00577","article-title":"Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments","volume":"8","author":"Weideman","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107389_bib0158","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1608543","article-title":"Plasma testosterone concentration is correlated with circulating immune cell abundance in transgender young people on gender-affirming hormone treatment","volume":"16","author":"White","year":"2025","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.msard.2026.107389_bib0017","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40120-020-00193-5","article-title":"Real-world safety and effectiveness of dimethyl fumarate in black or African American patients with multiple sclerosis: 3-year results from ESTEEM","volume":"9","author":"Williams","year":"2020","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2026.107389_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104794","article-title":"Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial","volume":"76","author":"Williams","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"14","key":"10.1016\/j.msard.2026.107389_bib0103","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1212\/WNL.0000000000002543","article-title":"CIHR Team in the Epidemiology and Impact of comorbidity on Multiple Sclerosis. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis","volume":"86","author":"Zhang","year":"2016","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826004244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826004244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:49:25Z","timestamp":1787921365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826004244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":163,"alternative-id":["S2211034826004244"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107389","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tailoring disease-modifying therapy approaches across multiple sclerosis sub-populations","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107389","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107389"}}